Yusuf ŞEFLEKÇİ

Ms. Yusuf ŞEFLEKÇİ

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2024 in Gene
Verified
Journal Article
Open access
AKAhmet Efe Köseoğlu
Ahmet Efe Köseoğlu
FÖFiliz Özgül
Filiz Özgül
EIElif Naz Işıksal
Elif Naz Işıksal
YŞYusuf ŞEFLEKÇİ
Yusuf ŞEFLEKÇİ
DTDeniz Tülümen
Deniz Tülümen
YMYağmur Ekenoğlu Merdan
Yağmur Ekenoğlu Merdan
Naegleria fowleri, the brain-eating amoeba, is a free-living amoeboflagellate with three different life cycles (trophozoite, flagellated, and cyst) that lives in a variety of habitats around the world including warm freshwater and soil. It causes a disease called naegleriasis leading meningitis and primary amoebic meningoencephalitis (PAM) in humans. N. fowleri is transmitted through contaminated water sources such as insufficiently chlorinated swimming pool water or contaminated tap water, and swimmers are at risk. N. fowleri is found all over the world, and most infections were reported in both developed and developing countries with high mortality rates and serious clinical findings. Until now, there is no FDA approved vaccine and early diagnosis is urgent against this pathogen. In this study, by analyzing the N. fowleri vaccine candidate proteins (Mp2CL5, Nfa1, Nf314, proNP-A and proNP-B), it was aimed to discover diagnostic/vaccine candidate epitopes and to design a multi-epitope peptide vaccine against this pathogen. After the in silico evaluation, three prominent diagnostic/vaccine candidate epitopes (EAKDSK, LLPHIRILVY, and FYAKLLPHIRILVYS) with the highest antigenicities were discovered and a potentially highly immunogenic/antigenic multi-epitope peptide vaccine (NaeVac) was designed against the brain-eating amoeba N. fowleri causing human meningitis.

30 January 2026 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
YŞYusuf ŞEFLEKÇİ
Yusuf ŞEFLEKÇİ
AKAhmet Efe Köseoğlu
Ahmet Efe Köseoğlu
RSRabia Erdoğdu Sever
Rabia Erdoğdu Sever
EIElif Naz Işıksal
Elif Naz Işıksal
FÖFiliz Özgül
Filiz Özgül
AEAbdulilah Ece
Abdulilah Ece

19 August 2026 in Molecules
Verified
Journal Article
Open access
PDF file
YŞYusuf ŞEFLEKÇİ
Yusuf ŞEFLEKÇİ
AYAlper Yilmaz
Alper Yilmaz
AEAbdulilah Ece
Abdulilah Ece
Caspase-1 is a crucial inflammatory cysteine protease that facilitates the maturation of pro-inflammatory cytokines such as interleukin-1β and interleukin-18, making it a significant therapeutic target for inflammatory diseases. However, existing caspase-1 inhibitors often face challenges like toxicity and suboptimal drug-like properties, underscoring the need for new inhibitors. This study employed an integrated computational strategy, combining quantitative structure–activity relationship (QSAR) modeling and application of this validated model to a large natural product database followed by molecular docking, rigorous binding free energy analysis and extended molecular dynamics simulations. Initially, a dataset of 185 caspase-1 inhibitors with experimentally reported pKi values (ranging from 4.05 to 9.24) was used to construct a QSAR model using Partial Least Squares (PLS) regression. The PLS-based QSAR model was developed with 18 descriptors out of 5799 calculated descriptors for each compound and 10 latent variables, demonstrating strong statistical performance with R2 values of 0.870 and 0.838 for the training and test sets, respectively, and leave-one-out cross-validation coefficient Q2LOO and 5-fold cross-validation (Q25-fold) values of 0.819 and 0.814, respectively. Y-randomization tests further confirmed the model’s robustness, as the randomized models exhibited significantly lower statistical parameters than the original model. The validated QSAR model was applied to 276,518 natural products in the LOTUS database. Subsequent molecular docking, Molecular Mechanics/General Born Surface Area (MM/GBSA) scoring, and Pan-Assay INterference Compounds (PAINS) and Chemical Frequent Hitter (ChemFH) filtering identified 14 candidate compounds, which were further evaluated using 300 ns molecular dynamics simulations. Among these, four natural products (LTS0162325, LTS0221286, LTS0016840, and LTS0070407) showed the most stable binding behavior and maintained persistent interactions with key catalytic and substrate-binding residues of caspase-1 in a mimicked physiological condition. Overall, this study highlights natural diterpenoids and coumarin glycosides as promising scaffolds for caspase-1 inhibition and demonstrates that integrating QSAR modeling with structure-based approaches provides an efficient strategy for discovering potential anti-inflammatory drug candidates.

15 April 2025
Verified
Book Chapter
Closed access
HBHatice Bashir
Hatice Bashir
NKNigar Sahra Karabul
Nigar Sahra Karabul
SÇSude Naz Çataltepe
Sude Naz Çataltepe
YKYağmur Kırbayır
Yağmur Kırbayır
YŞYusuf ŞEFLEKÇİ
Yusuf ŞEFLEKÇİ
MIMURAT IHLAMUR
MURAT IHLAMUR
Beyin tümörleri, yüksek ölüm oranları ve sınırlı tedavi seçenekleri nedeniyle ciddi bir sağlık sorunudur. Geleneksel yöntemler, cerrahi müdahale, radyoterapi ve kemoterapi gibi yaklaşımlar içermekle birlikte, kan-beyin bariyerini aşmakta yetersiz kalmaktadır. Bu durum, ilaçların tümöre ulaşmasını zorlaştırırken sağlıklı dokulara zarar verme riskini artırmaktadır.Nanoteknoloji, hedefe yönelik ilaç taşıma sistemleri geliştirerek kan-beyin bariyerini aşabilen, tümörlere doğrudan ulaşan ve yan etkileri azaltan tedavi seçenekleri sunmaktadır. Lipozomlar, polimerik miseller, dendrimerler ve lipid nanopartiküller gibi nanotaşıyıcılar, ilaçların tümör bölgesinde daha uzun süre kalmasını sağlayarak etkinliği artırmaktadır. Manyetik ve metal oksit nanopartiküller, gelişmiş görüntüleme yöntemleriyle erken teşhise katkıda bulunurken, teranostik nanopartiküller hem teşhis hem de tedaviyi birleştiren çözümler sunmaktadır.Nanoteknoloji, beyin kanseriyle mücadelede büyük umut vaat etse de, klinik kullanımı için biyouyumluluk, güvenlik ve uzun vadeli etkiler üzerine daha fazla araştırmaya ihtiyaç duyulmaktadır. Gelecekte bu teknolojinin hastaların yaşam süresi ve kalitesini artırmada devrim yaratması beklenmektedir.

28 April 2025 in Northwestern Medical Journal
Verified
Journal Article
Open access
PDF file
CYCüneyd Yavaş
Cüneyd Yavaş
YŞYusuf ŞEFLEKÇİ
Yusuf ŞEFLEKÇİ
RERecep Eröz
Recep Eröz
Aim: The goal is to classify Salmonella enterica using whole genome sequencing reads and explore their functional profiles. This approach simplifies resolving phylogenetic ambiguities in higher taxa compared to traditional methods. Materials and Methods: Salmonella paired-end reads (SRA: SRR27334358) were obtained from the NCBI database and analyzed for quality using FastQC v0.12.1, with low-quality reads trimmed by Trimmomatic v0.36. De novo genome assembly was performed by using Unicycler v0.4.8, with subsequent gene annotation by using RAST. TYGS was utilized for taxonomic analysis. ResFinder v.2.1 identified antimicrobial resistance genes, and PathogenFinder v.1.1 was used for pathogenicity prediction. MLST analyzed the allele profile. CRISPR regions and proteins were identified by CRISPRCasFinder, while AntiSMASH 7.0.1 determined secondary metabolites. SPIFinder detected pathogenicity islands, and the genome map was created using the CGView server. RAST performed genomic functional classification. Results: The genome, spanning 4,720,639 bp with 36 contigs, was analyzed by RAST, revealing 366 subsystems. TYGS showed a 100% dDDH with S. enteritidis ATCC 13076. The aac(6')-Iaa gene, conferring resistance to amikacin and tobramycin, was detected. PathogenFinder predicted S. enterica as a human pathogen with a 0.942 probability. MLST revealed 100% similarity with alleles of 7 housekeeping genes of Salmonella. CRISPRFinder identified eight Type I CRISPR-Cas proteins. AntiSMASH detected two secondary metabolites: enterobactin and O-antigen. SPIFinder identified 12 SPIs across the subspecies S. Typhimurium, S. Typhi, S. Enteritidis, S. Choleraesuis, and S. Gallinarum. Conclusion: The genome showed 100% digital DNA-DNA hybridization (dDDH) with Salmonella enteritidis ATCC 13076 and was identified as a human pathogen. Recognizing pathogenic strains is crucial for timely intervention, control strategy design, and targeted vaccine development.

11 November 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
ENEmir Nekay
Emir Nekay
SBSavas Baris
Savas Baris
ÖBÖzgür Balasar
Özgür Balasar
CYCüneyd Yavaş
Cüneyd Yavaş
YŞYusuf ŞEFLEKÇİ
Yusuf ŞEFLEKÇİ
IYIlknur Yilmaz
Ilknur Yilmaz
Background: Li–Fraumeni syndrome (LFS) is a clinically and genetically heterogeneous autosomal dominant hereditary cancer syndrome characterized by early-onset tumors, multiple primary cancers, and a strong family history of cancer. Unlike most hereditary cancer syndromes, LFS predisposes individuals to a broad spectrum of malignancies, including leukemia, brain tumors, soft-tissue sarcomas, breast cancer, adrenocortical carcinoma, and bone tumors. LFS is primarily associated with germline pathogenic variants in the TP53 gene. Herein, we report the clinical, genetic, and bioinformatic findings of a family with multiple early-onset LFS-associated cancers in which the pathogenic TP53 c.1024C>T, p.(Arg342*) variant was identified. Methods: DNA extracted from peripheral blood was analyzed using a 76-gene Hereditary Cancer Panel by next-generation sequencing. Variants were classified according to ACMG criteria using VarSome, Franklin, ClinVar, OMIM, PubMed, and in silico prediction tools. Wild-type TP53 structure (AF-P04637-F1) and the mutant structure were modeled, refined, and aligned using I-TASSER, ModRefiner, and UCSF Chimera to assess structural alterations. Evolutionary conservation was evaluated using ConSurf with Bayesian and maximum likelihood methods. Results: Family history revealed individuals who had previously undergone surgery for breast cancer. Subsequent cascade testing identified the TP53 variant in three relatives without a personal history of cancer, while deceased affected relatives were unavailable for testing. Conclusions: Individuals carrying pathogenic TP53 variants require genetic counseling and intensive surveillance for early cancer detection. Appropriate follow-up of cancer-free carriers may facilitate early diagnosis and reduce cancer-related mortality. Structural modeling indicated that p.(Arg342*) abolishes the TP53 tetramerization domain while preserving the DNA-binding core, suggesting that the variant acts as a null allele rather than through a dominant-negative mechanism.